套细胞淋巴瘤MCL诊治进展 (1).pptVIP

Author,year Regimen n Response,OR Median PFS Median OS Wang 2009 Zevalin d8 Rituximab 375mg/m2 34 31% 6 mo 21 mo O’Connor 2009 Bortezomib 1.5mg/m2 d1,4,8,11 40 47%(CR/CRu:13%) 5.3 mo n.a. Goy 2009 Bortezomib 1.3mg/m2 d1,4,8,11 141 33% 6.5 mo 23.5 mo Kaufmann 2004 Thalidomide 200mg Rituximab 375mg/m2 16 81%(CR/CRu:31%) 20.4 mo 75%(3y) Habermann 2009 Lenalidomide 25mg d1-21 15 53%(CR/CRu:20%) 5.6 mo n.a. Zinzani 2008 Lenalidomide 25mg d1-21 39 43%(CR/CRu:8%) 7.2 mo n.a. Witzig 2005 Temsirolimus 250mg weekly 35 38%(CR/CRu:3%) 6.5 mo 12 mo Hess 2008 Temsirolimus 175mg/75mg weekly Temsirolimus 1